Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of “patented” ATO is prohibitive because of patent rights. “Generic” ATO has been used in a few countries, but its implic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Bankar, Aniket, Korula, Anu, Kulkarni, Uday P., Devasia, Anup J., Fouzia, NA, Lionel, Sharon, Abraham, Aby, Balasubramanian, Poonkuzhali, Janet, Nancy Beryl, Nair, Sukesh C., Sezlian, S, Jeyaseelan, Visali, Jeyaseelan, N, Prasad, Jasmine, George, Biju, Mathews, Vikram
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7617145/
https://ncbi.nlm.nih.gov/pubmed/31863602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16343
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items